[1]李凤鹏 张军.2型心肌梗死和心肌损伤的研究进展[J].心血管病学进展,2019,(9):1275-1278.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.023]
　LI Fengpeng,ZHANG Jun.Type 2 Myocardial Infarction and Myocardial Injury[J].Advances in Cardiovascular Diseases,2019,(9):1275-1278.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.023]
点击复制

2型心肌梗死和心肌损伤的研究进展()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2019年9期
页码:
1275-1278
栏目:
综述
出版日期:
2019-12-25

文章信息/Info

Title:
Type 2 Myocardial Infarction and Myocardial Injury
作者:
李凤鹏1 张军1; 2
1.河北医科大学研究生学院,河北 石家庄 050000 ;2. 河北医科大学附属沧州市中心医院心内五科,河北 沧州 061001 )
Author(s):
LI Fengpeng1; ZHANG Jun1; 2
Hebei Medical University Graduate School,Shijiazhuang,050000,Hebei,China; 2.Department of Cardiovascular V, Cangzhou Central Hospital,Hebei Medical University,Changzhou 061000,Hebei,China)
关键词:
2型心肌梗死; 心肌损伤; 1型心肌梗死
Keywords:
Type 2 myocardial infarction; Myocardial injury; Type 1 myocardial infarction
DOI:
10.16806/j.cnki.issn.1004-3934.2019.09.023
摘要:
2型心肌梗死是指由继发于耗氧量增加或氧供减少导致的心肌损伤。2型心肌梗死和心肌损伤的发生机制差别很大，其治疗方式和预后也不尽相同，因此及时的诊断有助于个体化诊疗方案的实施。现对2型心肌梗死和心肌损伤的发病机制特点和诊疗策略的研究进展做一综述。
Abstract:
Type 2 myocardial infarction(T2MI) refers to myocardial injury/necrosis secondary to increased oxygen consumption or decreased oxygen supply.The mechanism of T2MI is different from myocardial injury, as well as its treatment and prognosis, so timely diagnosis is helpful to the implementation of individualized therapy. The purpose of this paper is to review the pathogenesis, diagnosis, and treatment strategies of T2MI and myocardial injury.

参考文献/References:


[1] Thygesen K, Alpert JS, Jaffe AS, et al. Fourth Universal definition of myocardial infarction (2018)[J]. Glob Heart,2018,13(4):305-338.

[2] Saaby L, Poulsen TS, Hosbond S, et al. Classification of myocardialinfarction: frequency and features of type 2 myocardial infarction[J]. Am J Med, 2013,126(9):789-797.

[3] Hijazi Z, Oldgren J, Andersson U, et al. Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) substudy[J]. Circulation, 2012,125(13):1605-1616.

[4] Chen JF, Smilowitz NR, Kim JT, et al. Medical therapy for atherosclerotic cardiovascular disease in patients with myocardial injury after non-cardiac surgery[J]. Int J Cardiol, 2019,279: 1-5.

[5] Gualandro DM, Campos CA, Calderaro D, et al. Coronary plaque rupture in patients with myocardial infarction after noncardiac surgery: frequent and dangerous[J]. Atherosclerosis, 2012,222(1):191-195.

[6] Samman TA, Sandesara P, Hayek SS, et al. High-sensitivity troponin I levels and coronary artery disease severity, progression, and long-term outcomes[J]. J Am Heart Assoc,2018,7(5):e007914.

[7] Alpert JS, Thygesen KA, White HD, et al. Diagnostic and therapeutic implications of type 2 myocardial infarction: review and commentary[J]. Am J Med, 2014,127(2):105-108.

[8] White HD. Pathobiology of troponin elevations: do elevations occur with myocardial ischemia as well as necrosis?[J]. J Am Coll Cardiol, 2011,57(24):2406-2408.

[9] Park KC, Gaze DC, Collinson PO, et al. Cardiac troponins: from myocardial infarction to chronic disease[J]. Cardiovasc Res, 2017, 113(14):1708-1718.

[10] Costabel JP, Burgos LM, Trivi M. The Significance of troponin elevation in atrial fibrillation[J]. J Atr Fibrillation,2017,9(6):1530.

[11] Chin CW, Shah AS, McAllister DA, et al. High-sensitivity troponin I concentrations are a marker of an advanced hypertrophic response and adverse outcomes in patients with aortic stenosis[J]. Eur Heart J, 2014,35(34): 2312-2321.

[12] Chapman AR, Adamson PD, Mills NL. Assessment and classification of patients with myocardial injury and infarction in clinical practice[J]. Heart,2017,103(1):10-18.

[13] Vasile VC, Chai HS, Abdeldayem D, et al. Elevated cardiac troponin T levels in critically ill patients with sepsis[J]. Am J Med, 2013,126(12):1114-1121.

[14] Thygesen K, Mair J, Giannitsis E, et al. How to use high-sensitivity cardiac troponins in acute cardiac care[J]. Eur Heart J, 2012,33(18):2252-2257.

[15] Chapman AR, ASV S, Lee KK, et al. Long-term outcomes in patients with type 2 myocardial infarction and myocardial injury[J].Circulation,2018,137(12): 1236-1245.

[16] Radovanovic D, Pilgrim T, Seifert B, et al. Type 2 myocardial infarction: incidence, presentation, treatment and outcome in routine clinical practice[J]. J Cardiovasc Med, 2017,18(5):341-347.

相似文献/References:

[1]冯泽豪 姜萌 卜军.心脏磁共振评价化疗所致心肌损伤的研究进展[J].心血管病学进展,2019,(5):667.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.003]
　FENG Zehao,JIANG Meng,PU Jun.Cardiovascular Magnetic Resonance for Detection of Myocardial Impairments Caused by Chemotherapy[J].Advances in Cardiovascular Diseases,2019,(9):667.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.003]
[2]布热比古力·阿布力米提 付真彦.乳腺癌药物治疗与心肌损伤[J].心血管病学进展,2020,(8):802.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.005]
　Burebiguli·abulimitiFU Zhenyan.Drug Therapy of Breast Cancer and Assosiated Myocardial Damage[J].Advances in Cardiovascular Diseases,2020,(9):802.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.005]
[3]陈涛 张大勇 袁明 魏天龙.急性ST段抬高型心肌梗死患者血miRNA-499a与心肌损伤标志物的相关性分析[J].心血管病学进展,2020,(9):994.[doi:10.16806/j.cnki.issn.1004-3934.2020.09.025]
　CHEN Tao,ZHANG Dayong,YUAN Ming,et al.Correlation Between Serum miRNA-499a and Myocardial Injury Markers in Patients with Acute ST-Segment Elevation Myocardial Infarction[J].Advances in Cardiovascular Diseases,2020,(9):994.[doi:10.16806/j.cnki.issn.1004-3934.2020.09.025]
[4]汪汉,刘汉雄,蔡琳.2019冠状病毒病的心血管表现[J].心血管病学进展,2020,(11):1152.[doi:10.16806/j.cnki.issn.1004-3934.2020.11.000]
　WANG Han,LIU Hanxiong,CAI Lin.Cardiovascular Profiles in Corona V irus Disease 2019[J].Advances in Cardiovascular Diseases,2020,(9):1152.[doi:10.16806/j.cnki.issn.1004-3934.2020.11.000]
[5]庞泽堃 李剑明.放射性核素分子显像在心肌损伤中的研究进展[J].心血管病学进展,2023,(1):25.[doi:10.16806/j.cnki.issn.1004-3934.2023.01.007]
　PANG Zekun,LI Jianming.Radionuclide Molecular Imaging in Myocardial Injury[J].Advances in Cardiovascular Diseases,2023,(9):25.[doi:10.16806/j.cnki.issn.1004-3934.2023.01.007]
[6]田振宇 刘燕娥 朱丹 曹宝山 崔鸣.肿瘤化疗心肌损伤机制及其与肠道菌群相关性的研究进展[J].心血管病学进展,2023,(6):496.[doi:10.16806/j.cnki.issn.1004-3934.2023.06.004]
　TIAN Zhenyu,LIU Yane,ZHU Dan,et al.Progress of the Mechanism of Myocardial Injury and its Correlation between Tumor Chemotherapy and Intestinal Microbiota[J].Advances in Cardiovascular Diseases,2023,(9):496.[doi:10.16806/j.cnki.issn.1004-3934.2023.06.004]
[7]袁敏?韩轩茂?蔺雪峰.纳米氧化铈抗氧化保护心肌细胞的研究进展[J].心血管病学进展,2023,(7):654.[doi:10.16806/j.cnki.issn.1004-3934.2023.07.018]
　YUAN Min,HAN Xuanmao,LIN Xuefeng.Cerium Oxide Nanoparticles in Antioxidant Protection of M yocardial?ells?/html>[J].Advances in Cardiovascular Diseases,2023,(9):654.[doi:10.16806/j.cnki.issn.1004-3934.2023.07.018]
[8]冉黔松 周厚荣.长链非编码RNA调节自噬在心肌缺血再灌注损伤中的研究进展[J].心血管病学进展,2024,(3):238.[doi:10.16806/j.cnki.issn.1004-3934.2024.03.011]
　RAN Qiansong ZHOU Hourong.Long Non-Coding RNA Regulating Autophagy in Myocardial Ischemia-Reperfusion Injury[J].Advances in Cardiovascular Diseases,2024,(9):238.[doi:10.16806/j.cnki.issn.1004-3934.2024.03.011]
[9]富悦 任家孚 阿荣.白细胞介素-13与免疫细胞相互作用在心血管疾病中的研究进展[J].心血管病学进展,2024,(4):345.[doi:10.16806/j.cnki.issn.1004-3934.2024.04.013]
　FU Yue,REN Jiafu,A Rong.Interaction of Interleukin-13 and Immunocyte in Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2024,(9):345.[doi:10.16806/j.cnki.issn.1004-3934.2024.04.013]
[10]张晓 姬红梅 高洁 董心莹 刘胜囡 韩宇 尹心心 蒋丽军 王甲莉 陈玉国.2型心肌梗死诊断及预后的研究进展[J].心血管病学进展,2024,(6):510.[doi:10.16806/j.cnki.issn.1004-3934.2024.06.008]
　ZHANG Xiao,JI Hongmei,GAO Jie,et al.Diagnosis and Prognosis of Type 2 Myocardial Infarction[J].Advances in Cardiovascular Diseases,2024,(9):510.[doi:10.16806/j.cnki.issn.1004-3934.2024.06.008]

更新日期/Last Update: 2020-02-06